EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Drug development advances in human genetics‐based targets

Xiaoxia Zhang iD, Wenjun Yu, Yan Li, Aiping Wang, Haiqiang Cao, Yuanlei Fu

MedComm · 2024-02 · 5 (2)

DOI: 10.1002/mco2.481 ↗

At a glance

Übersichtsarbeit in MedComm, published online on 2024-02-09. Written by Xiaoxia Zhang and 5 co-authors. Institution: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Cited 21 times so far (Crossref); 314 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Drug development is a long and costly process, with a high degree of uncertainty from the identification of a drug target to its market launch. Targeted drugs supported by human genetic evidence are expected to enter phase II/III clinical trials or be approved for marketing more quickly, speeding up the drug development process. Currently, genetic data and technologies such as genome‐wide association studies (GWAS), whole‐exome sequencing (WES), and whole‐genome sequencing (WGS) have identified and validated many potential molecular targets associated with diseases. This review describes the structure, molecular biology, and drug development of human genetics‐based validated beneficial loss‐of‐function (LOF) mutation targets (target mutations that reduce disease incidence) over the past decade. The feasibility of eight beneficial LOF mutation targets (PCSK9, ANGPTL3, ASGR1, HSD17B13, KHK, CIDEB, GPR75, and INHBE) as targets for drug discovery is mainly emphasized, and their research prospects and challenges are discussed. In conclusion, we expect that this review will inspire more researchers to use human genetics and genomics to support the discovery of novel therapeutic drugs and the direction of clinical development, which will contribute to the development of new drug discovery and drug repurposing.

Subjects

Author keywords

drug developmentdrug targetgenetic variationgenome‐wide association studieswhole‐exome sequencingwhole‐genome sequencing

Authors and institutions

  • School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica Yantai Shandong China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery Yantai Shandong China.
  • State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai China.

ORCID profiles: Xiaoxia Zhang

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Cite

APA

Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024). Drug development advances in human genetics‐based targets. MedComm, 5(2). https://doi.org/10.1002/mco2.481

Vancouver

Zhang X, Yu W, Li Y, Wang A, Cao H, Fu Y. Drug development advances in human genetics‐based targets. MedComm. 2024;5(2). doi:10.1002/mco2.481

BibTeX
@article{Zhang2024,
  author = {Zhang, Xiaoxia and Yu, Wenjun and Li, Yan and Wang, Aiping and Cao, Haiqiang and Fu, Yuanlei},
  title = {Drug development advances in human genetics‐based targets},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {2},
  doi = {10.1002/mco2.481}
}
Start for free →